HotSpot
is a Massachusetts-based biotechnology company that develops and commercializes small molecule drugs for the treatment of cancer and autoimmune diseases... Read moreHotSpot
is a Massachusetts-based biotechnology company that develops and commercializes small molecule drugs for the treatment of cancer and autoimmune diseases... Read more
News
Jun 04, 2026
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
Mar 04, 2026
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
Jul 08, 2025
Pharmabiz
HotSpot: HotSpot presents preclinical data from small molecule CBM signalosome inhibitor programme at ESMO Gastrointestinal Cancers Congress 2025
Jun 26, 2025
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
Jun 18, 2025
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
Oct 09, 2024
StreetInsider
Press Release: HotSpot : HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
Oct 04, 2024
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
Jun 20, 2024
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
May 20, 2024
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
Dec 11, 2023
PR Newswire
Press Release: HotSpot : HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting
HotSpot Competitors
1
2
3
4
5
6
7
8
9
10